Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2006-10-25

FDA Approved: COMBIVIR — Supplemental Application (ViiV Healthcare Company)

View source ↗

Summary

The FDA approved a supplemental application for COMBIVIR (lamivudine and zidovudine) from ViiV Healthcare Company.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • COMBIVIR (Lamivudine and Zidovudine)

Snippet

SUPPL AP for COMBIVIR (LAMIVUDINE AND ZIDOVUDINE)